These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36890938)

  • 1. Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints.
    Sachu A
    Ethiop J Health Sci; 2023 Jan; 33(1):143-150. PubMed ID: 36890938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
    Urbán E; Stone GG
    Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.
    Khan A; Rivas LM; Spencer M; Martinez R; Lam M; Rojas P; Porte L; Silva F; Braun S; Valdivieso F; Mv Lhauser M; Lafourcade M; Miller WR; García P; Arias CA; Munita JM
    J Clin Microbiol; 2019 Sep; 57(9):. PubMed ID: 31315958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
    Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
    Lahiri SD; McLaughlin RE; Whiteaker JD; Ambler JE; Alm RA
    J Antimicrob Chemother; 2015 Sep; 70(9):2488-98. PubMed ID: 26045529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018.
    Karlowsky JA; Hackel MA; Bouchillon SLK; Lowman W; Kotb REM; Mohamed N; Stone GG; Sahm DF
    J Glob Antimicrob Resist; 2021 Mar; 24():249-256. PubMed ID: 33373731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
    Alfouzan W; Boswihi SS; Dhar R; Udo E
    J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftaroline against mecC-positive MRSA isolates.
    Armengol-Porta M; Tenorio-Abreu A; Bandt D; Coleman DC; Gavier-Widen D; Hotzel H; Kinnevey P; Lazaris A; Peters M; Rangstrup-Christensen L; Schlotter K; Shore AC; Ehricht R; Monecke S
    J Glob Antimicrob Resist; 2016 Jun; 5():3-6. PubMed ID: 27436457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
    Andrey DO; François P; Manzano C; Bonetti EJ; Harbarth S; Schrenzel J; Kelley WL; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
    Mengeloğlu FZ; Taş T; Koçoğlu E; Copur Çiçek A; Yanık K; Güneş H; Ciftci IH; Durmaz S; Bucak O; Güçkan R; Terzi HA; Yavuz MZ
    Mikrobiyol Bul; 2013 Oct; 47(4):677-83. PubMed ID: 24237436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.
    Piérard D; Stone GG
    J Glob Antimicrob Resist; 2021 Sep; 26():4-10. PubMed ID: 34022417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital.
    Siddiqui T; Sahu C; Patel SS
    Indian J Med Microbiol; 2022; 40(1):101-104. PubMed ID: 34481692
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk.
    Koeth LM; Matuschek E; Kahlmeter G; Alm RA; Ambler JE
    Eur J Clin Microbiol Infect Dis; 2014 Sep; 33(9):1511-7. PubMed ID: 24744220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
    Zhang H; Xiao M; Kong F; O'Sullivan MV; Mao LL; Zhao HR; Zhao Y; Wang H; Xu YC
    Int J Antimicrob Agents; 2015 Apr; 45(4):347-50. PubMed ID: 25649348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and molecular epidemiology of ceftaroline non-susceptible methicillin-resistant Staphylococcus aureus isolates, first clinical report from Iran.
    Khoshbayan A; Shariati A; Ghaznavi-Rad E; van Belkum A; Darban-Sarokhalil D
    Acta Microbiol Immunol Hung; 2020 Dec; 67(4):228-233. PubMed ID: 33258796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
    Jones RN; Farrell DJ; Mendes RE; Sader HS
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii69-80. PubMed ID: 21482572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.